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Endometrial carcinoma: molecular alterations involved in tumor
development and progression
A Yeramian1, G Moreno-Bueno2, X Dolcet1, L Catasus3, M Abal4, E Colas5, J Reventos5, J Palacios6, J Prat3 and X Matias-Guiu1
In the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence
has been estimated at 10--20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I,
endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by
specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue
deleted on chromosome 10, PIK3CA, K-RAS and CTNNB1 (b-catenin), and type II exhibiting TP53 mutations and chromosomal
instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor
progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular
levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is
essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial
carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors.
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INTRODUCTION
In western countries, endometrial carcinoma (EC) is the most
common cancer of the female genital tract. EC occurs in peri- and
postmenopausal women, although it may also be present in
premenopausal women, particularly in the setting of hyperestro-
genism. From a clinical viewpoint, EC falls into two different types,
so-called types I and II.1 Type I tumors are low-grade and
estrogen-related endometrioid endometrial carcinomas (EECs)
that usually develop in perimenopausal women and coexist or
are preceded by endometrial hyperplasia. In contrast, type II
tumors are non-endometrioid endometrial carcinomas (NEECs).
These aggressive tumors that occur in older women, are unrelated
to estrogen stimulation and arise occasionally in endometrial
polyps or from precancerous lesions in atrophic endometrium.
Over the last 15 years, knowledge about the molecular genetics
of EC has increased notably. However, some issues remain to be
elucidated and will be discussed in this review.
MOLECULAR FEATURES OF TYPES I AND II EC
It has been demonstrated that the molecular genetic alterations
involved in the development of EEC (type I) differ from those of
NEEC (type II).2 - 4 First, complementary DNA (cDNA) analysis
clearly shows that EEC and NEEC have different gene expression
profiles. Moreover, whereas EEC shows microsatellite instability
(MI) and mutations in the phosphatase and tensin homologue
deleted on chromosome 10 (PTEN), PIK3CA, K-RAS and b-catenin
genes, NEEC have alterations of p53, loss of heterozygosity (LOH)
on several chromosomes, as well as other molecular alterations
(STK15, p16, E-cadherin and C-erbB2).
MI was initially noted in cancers of patients with the hereditary
non-polyposis colorectal carcinoma (HNPCC), but also in sporadic
colon cancers. EC is the second most common tumor found in
HNPCC patients. MI is seen in 75% of EC associated with HNPCC,
but also in 25--30% of sporadic EC.5 - 8 HNPCC patients have an
inherited germline mutation in MLH1, MSH2, MSH6 or PMS2. MI
occurs more frequently in EEC (30%) than in NEEC. In sporadic
tumors, MLH1 inactivation by promoter hypermethylation is the
main cause of mismatch repair deficiency.9 The MI-associated
mismatch repair deficiency leads to the accumulation of muta-
tions in coding and non-coding DNA sequences. Some small
short-tandem repeats, like mononucleotide repeats, located within
the coding sequence of some important genes; (BAX, IGFIIR, MSH3,
MSH6, MBD4, CHK1, CASP5, ATR, ATM, BML, RAD50, BCL10 and
APAF1) are targets in the process of tumor progression of MIþ EC.
Mutations in these tracts are interpreted as secondary events in
cancers with MI.10,11
The tumor-suppressor gene PTEN is frequently abnormal in
EC.12 - 14 LOH at chromosome 10q23 occurs in 40% of EC.15
Somatic PTEN mutations are also common in EC, and they are
almost exclusively restricted to EEC, occurring in 37--61% of them
and lead to activation of the PI3K/AKT pathway. There are many
evidences showing that EECs with mutations in PTEN have
genomic instability.16 For that reason, some authors have
suggested to treat patients with PARP inhibitors.17 Mutations in
PIK3CA may contribute to the alteration of the phosphatidylino-
sitol 3 kinase (PI3K)/AKT signaling pathway in EC.18 - 20 PI3K is a
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heterodimeric enzyme consisting of a catalytic subunit (p110) and
a regulatory subunit (p85).The PIK3CA gene codes for the p110a
catalytic subunit of PI3K. A high frequency of mutations in the
PIK3CA gene has been reported recently in EC. Mutations are
predominantly located in the helical (exon 9) and kinase (exon 20)
domains, but they can occur also in exons 1 to 7.21 PIK3CA
mutations occur in 24--39% of the cases, and coexisted frequently
with PTEN mutations. PIK3CA mutations, particularly in exon 20,
have been associated with adverse prognostic factors such as
high-grade and myometrial invasion. Although initially described
in EEC, PI3KCA mutations also occur in NEEC, and also mixed EEC--
NEEC.22,23 Furthermore, gene expression profile differences in the
PI3K--AKT signaling pathway identify two subgroups of high-
grade EC with different molecular alterations (PI3K/AKT pathway
versus p53 alterations), which may play distinct roles in
endometrial carcinogenesis.24 Moreover, mutations in PIK3RI
(p85a), the inhibitory subunit of PI3K, have been detected in
43% of EEC, and 12% of NEEC.25
Among AKT targets, downstream effector mammalian target of
rapamycin (mTOR) is of particular interest. mTOR inhibitors have
been recently developed as potential anticancer agents. Tumors
associated with PTEN inactivation, like EC, are particularly
susceptible to the therapeutic effects of mTOR inhibitors.
Pharmacological inhibition of mTOR in PTENþ / mice has shown
reduced neoplastic proliferation, tumor size and S6K activity.26
Moreover, the use of dual PI3K--mTOR has been proposed as a
targeted therapy, because they may target p110a, b and d
isoforms, mTORC1 and mTORC2.27 These inhibitors are expected
to be effective in cancers (like EC) with PTEN mutations, PIK3CA
mutations and receptor tyrosine kinase-dependent activation.
The Rat Sarcoma Viral Oncogene Homolog (Ras)--Raf proto-
oncogene serine/threonine-protein kinase (Raf)--Extracellular
Signal-Regulated Kinase kinase (MEK)--Extracellular Signal-
Regulated Kinase (ERK) signaling pathway plays an important role
in EC. The frequency of K-RAS mutations in EC ranges between 10
and 30%.28 BRAF, another member of the RAS--RAF--MEK--ERK
pathways is very infrequently mutated in EC.29 Recent studies
have demonstrated that RASSF1A inactivation by promoter
hypermethylation may contribute significantly to increased
activity of the RAS--RAF--MEK--ERK signaling pathway.30
There are several evidences suggesting that the fibroblast
growth factor (FGF) signaling pathway is important in EC. Recent
studies have shown that EC presents frequent inactivation of
SPRY-2, a protein that is involved in the negative regulation of the
FGFR pathway.31 Moreover, somatic mutations in FGFR2, identical
to the germline mutations associated with craniosynostosis and
skeletal dysplasia syndromes, have been recently detected in 10--
12% of EC, particularly in EEC (16%).32 - 34 FGFR-2 is of special
interest, since it is a possible target for therapeutic approaches.
Mutations in exon 3 of b-catenin gene (CTNNB1) occur in 14 to
44% of EC,35 - 37 and result in stabilization of the protein,
cytoplasmic and nuclear accumulation, and participation in signal
transduction and transcriptional activation through the formation
of complexes with DNA binding proteins. They appear to be
independent of the presence of MI, and the mutational status of
PTEN and K-RAS. Mutations are homogeneously distributed in
different areas of the tumors, which suggest that they do play a
role in early steps of endometrial tumorigenesis. The presence of a
cytoplasmic and nuclear b-catenin immunoreactivity in some ECs
that did not show a mutation in CTNNB1 suggests that alterations
in other genes of the Wnt/b-catenin/LEF-1 pathway may be
responsible for the stabilization and putative transcription
activator role of b-catenin in these tumors.38,39
In contrast to EEC, NEEC show P53 mutations (90%), inactivation
of p16 (40%) and E-cadherin (80--90%), c-erbB2 amplification
(30%), alterations in genes involved in the regulation of the
mitotic spindle checkpoint (STK15) and LOH at multiple loci,
reflecting the presence of chromosomal instability.40 - 44 Although
P53 mutations occur in 90% of NEEC, they are only present in
10--20% of EEC, which are mostly grade 3 tumors.45 Inactivation of
the cell cycle regulator p16 is also more frequent in NEEC (40%)
than in EEC (10%). The underlying mechanism is not clear, but
probably involves deletion and promoter hypermethylation.
Reduced expression of E-cadherin is frequent in EC, and may be
caused by LOH or promoter hypermethylation. In fact, LOH at
16q22.1 is seen in almost 60% of NEEC, but only in 22% of EEC. C-
erbB2 overexpression and amplification are also seen more
frequently in NEEC (43 and 29%) than in EEC. However, the most
typical molecular feature of NEEC is chromosomal instability. This
phenomenon is characterized by the presence of widespread
chromosomal gains and losses, which reflect the presence of
aneuploidy. cDNA arrays have demonstrated that NEEC usually
show upregulation of genes (STK15, BUB1 and CCNB2) that are
involved in the regulation of the mitotic spindle checkpoint. One
of them, STK15, which is essential for chromosome segregation
and centrosome functions, is frequently amplified in NEEC.
Among NEEC, clear cell carcinomas show specific features.
Based on the similarities between ovarian and endometrial clear
cell carcinoma, it has been suggested that both types of tumors
may exhibit similar alterations, including mutations in PIK3CA and
PTEN. Mutation of the ARID1A gene and loss of the corresponding
protein BAF250a has recently been described as a frequent event
in clear cell and endometrioid carcinomas of the ovary. In a recent
study, these changes have been found in 29% of grade 1 or 2 and
39% of grade 3 EEC, 18% of uterine serous carcinomas and 26% of
uterine clear cell carcinomas. In a different study, uterine low-
grade EEC have also shown a relatively high-frequency loss of
ARID1A expression (26%) and ARID1A mutations (40%).46,47
cDNA array studies have demonstrated that the expression
profiling of EEC is different from that of NEEC. Some of the data
obtained from these studies have helped in a better diagnosis and
prognosis. In one study,48 191 genes exhibited a greater twofold
differences between 19 EECs and 16 NEECs. One of the genes,
trefoil factor 3 (TFF3) was significantly upregulated in EECs, while
increased expression of folate-binding protein (FOLR) was seen in
NEECs. Subsequent studies demonstrated that TFF3 was highly
expressed at gene and protein level in high-grade EECs,
suggesting that TFF3 could be a novel serum marker for early
detection and/or monitoring EEC patients.49 Moreover, over-
expression of FOLR and mesothelin was found to be associated
with NEEC,50 and also with shortened progression-free survival in
EC.51 In a different study, a different expression profile was seen
between EEC and NEEC, and the differences involved 66 genes.
Interestingly, estrogen-regulated genes were upregulated in EEC,
whereas NEEC showed increased expression of genes involved in
the regulation of the mitotic spindle checkpoint.52 A third study
demonstrated differentially expression of 1055 genes between
EECs and serous carcinomas. Genes that were differentially
expressed were IGF2, PTGS1, p16, TFF3, FOXA2 and MSX2.53
A different study identified 315 genes that statistically differ-
entiated EEC from NEEC.54 Among the genes listed for EEC are
ras-related protein RAB14, a2-catenin, human transforming growth
factor b3 and ILGF1. In contrast, aldolase C was one of the major
discriminators for NEEC. In a different study, it was seen that the
tumors (ovarian and uterine) with b-catenin alterations, showed
common gene expression profile.55 Recently, a low-density cDNA
microarray approach identified five differentially expressed genes
in EEC and NEEC, NDC80, BUB1, FUT8, ANXA4 and BBC3.56
Moreover, a different expression profile was also found between
EC associated with MI and stable EC. Interestingly, two members
of the secreted frizzled related protein family (SFRP1 and SFRP4)
were more frequently downregulated in EC with MI.57
Molecular profiling has also been evaluated in relationship with
other prognostic parameters. A recent study with an array
containing 492 genes was used to generate gene expression
profiles in correlation with histologic type and grade, and stage.58
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One cluster contained 38 genes that were upregulated in samples
of the cluster representing the most advanced disease; and one of
these genes was CCNE2. Gene expression profiling also has
revealed that some genes (Apolipoprotein E) are differentially
expressed in poorly differentiated tumors.59 Our group has also
identified, by c-DNA array studies, upregulation of RUNX1/AML1
and ERM/ETV5 in EC,60 and suggested an implication of such genes
in myometrial invasion. One study compared the expression
profiles of similar histological subtypes of ovarian and ECs; and
showed that clear cell carcinomas had a very similar profile,
regardless of the organ of origin. In contrast, differences were seen
when comparing endometrioid and serous carcinomas of ovarian
and endometrial origin.
We have recently performed a cDNA microarray analysis to
identify new genes and pathways involved in endometrial
carcinogenesis. We used cDNA microarrays containing 6386
different genes to analyze gene expression profiles in 24 EECs and
8 normal endometria (NE) samples. After supervised analysis of the
microarray data, there was an at least twofold difference in
expression between EEC and NE in 159 genes (adjusted P-values
o0.07, unadjusted P-values o0.001), including, among others,
tumor-suppressor genes (SMAD4 and WT1), genes involved in
endometrial homeostasis (IGF1, IGF2), immune modulation (CD74,
LCN2, IL2, IL5R and IL7R), the Wnt pathway (WNT5A and DVL2),
mismatch repair (PMS1), cell signaling (FGFR1, PGFRA, PLXNB1, KSR,
LYN, FYN, PRKCD, STAT3 and STAT12), components of the
extracellular matrix (SPARC, COL5A1, COL5A2, COL5A1, COL6A3 and
COL15A1) and genes involved in extracellular matrix remodeling
(MMP9 and MMP19). To validate the quality of our array
data, a subset of genes (IGF1, IGF2, WNT5A, WT1, PMS1, PRKCD and
FGFR1) differentially expressed in normal endometrium and EECs
were examined in all samples using semi-quantitative reverse
transcriptase--PCR and also in an independent series of EECs
obtaining similar results, with the only exception was PRKCD, which
just failed to reach significance, with a P-value of 0.079 (Table 1;
Figure 1). In addition, CD74 and Smad4, were immunohistochemi-
cally analyzed in a tissue microarray containing 190 ECs, including
both EEC and NEEC, in order to further validate microarray data and
to gain insights into the role of these proteins in EC (Table 2).
Immunohistochemical analysis demonstrated that CD74, which was
not expressed in normal endometrium, was expressed in 123
(80.4%) tumors and was associated with the endometrioid
phenotype and lower grade. Finally, Smad4 expression was reduced
in 75 (57.3%) tumors, including 17 (13%) cases with complete
absence of Smad4 expression in neoplastic epithelial cells (Figure 2).
ECs not fitting within the dualistic (type I versus type II) model
The classification of EC into two groups (type I and type II) is
artificial and too rigid and the dualistic model needs to be
challenged (Figure 3). In daily practice, pathologists are faced with
tumors showing combined or hybrid morphologic and molecular
characteristics (often endometrioid and serous tumors). Further-
more, even if serous and clear cell carcinomas have been classified
within the same category of tumors as they are more aggressive
than EC, recent studies have shown that these are in fact distinct
tumor types, as they exhibit different clinical, immunohistochem-
ical and molecular features. When an EC has an admixture of EEC
and EC, with the minor component representing at least 10% of
the neoplasm, the tumor should be classified as a mixed
carcinoma. Based on molecular analysis, it has been suggested
that the NEEC component originates as a result of tumor
progression from a pre-existing EEC, because frequently these
tumors retain the molecular alterations of typical EEC. There are
some tumors that exhibit overlapping and intermediate features
between EEC and NEEC and fail to show two distinct components.
The term ‘EC with ambiguous features’ has been proposed for
these carcinomas.61 Their clinical and molecular features should
be defined better. Moreover, the overlap between EEC and NEEC is
also seen when we look for differences in the frequency of the
main molecular alteration. The typical molecular alterations of EEC
are occasionally seen in NEEC, while the typical molecular features
of NEEC are also detected in EEC.
Occasionally, undifferentiated carcinomas are associated with
well- or moderately differentiated EEC. The term dedifferentiated
carcinoma has been used to designate such special type of tumor.
Several groups of investigators have reported that the EECs with a
tendency to develop a high-grade, undifferentiated carcinoma
present MI as a frequent molecular genetic alteration.62 However,
MI is not seen in all cases and other, have P53 mutations.
Malignant mixed müllerian tumors (MMMT), (carcinosarconas or
sarcomatoid carcinomas), are uncommon uterine neoplasms. They
are composed by a bifasic pattern, with epithelial malignant
elements and a sarcomatoid component. It has recently suggested
from the molecular point of view that MMMT should be regarded
as metaplastic carcinomas.63 - 65 Like sarcomatoid carcinomas of
other locations, carcinosarcomas probably develop through
epithelial-to-mesenchymal transition (EMT) in EC. Although the
transient occurrence of the EMT phenomenon is important for
myometrial invasion in conventional EC, MMMT show permanent
expression of EMT leading to repression of epithelial markers
(E-cadherin) and increased expression of mesenchymal markers
including proteins involved in skeletal muscle development. All of
these molecular changes are responsible for the appearance of
the sarcomatous areas as well as the presence of heterologous
differentiation. It has been recently seen that MMMT show HMGA2
overexpression, and a microRNA signature typical of EMT.66,67
MYOMETRIAL INVASION
Deep myometrial invasion is an important prognostic factor. It
correlates with high-grade components, vascular invasion and
lymph node metastasis. EMT has recently been recognized as an
important mechanism in invasion and metastasis. Different
transcriptional repressors of E-cadherin have been identified,
including the zinc-finger factors Snail and Slug, the two handed
factors SIP-1 (Zeb-2) and EF1 (Zeb-1), and the bHLH factors E12/
E47 and Twist. Snail expression is increased and correlates
inversely with E-cadherin inmunoreactivity in metastatic EC but
not in the corresponding primary tumors.68 Nevertheless, a
significant negative correlation between E-cadherin decrease
and Snail expression has also been found in primary EC.
Furthermore, high Twist expression has been shown in invasive
EC. Our group69 has recently compared samples from the
surface area and the myoinvasive front of EC in order to
investigate whether the EMT program is activated in early stages
of EC. We found increases in SLUG, ZEB1 and HMGA2 mRNA
expression in the myoinvasive front of tumor samples, indicating
the role of these transcriptional factors in endometrial tumor
progression and invasion. Increase in Snail and Twist expression
occurred concomitantly with decrease in E-cadherin expression at
the myoinvasive front of early stage EC. For better understanding
of the potential role of EMT in the genesis and development of
ECC, an in vitro scenario mimicking this process was developed
using IK V600E transformed EC cells. The overexpression of the
BRAF missense mutation V600E leads to a persistent activation of
ERK1/2 and increase in Snail protein levels as demonstrated by
immunofluorescence and western blot analysis.69
Also related to EMT, Ets transcription factors have been
associated with the activation of matrix-degrading proteases.70,71
Upregulation of ERM/ETV5, a member of the Ets transcription
factors, has been recently associated with initial steps of
myometrial invasion in EC, in correlation with increased matrix
metalloproteinase (MMP) 2. Higher expression of MMPs (MMP2,
MMP9) in EC, has been recently associated with invasive
and aggressive behavior in NEEC. Moreover, increased MMP7
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IL13RA1 2.0 AA478570, interleukin 13 receptor, alpha 1
ITGAL 2.0 R48796, integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)
LTB 2.1 AI351740, lymphotoxin beta (tumor necrosis factor (TNF) superfamily, member 3)
NFKBIA 2.1 W55872, nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, alpha
NFKBIE 2.1 AA953975, nuclear factor of kappa light polypeptide gene enhancer in B-cell inhibitor, epsilon
IL5RA 2.1 AI381503, interleukin 5 receptor, alpha
SCYD1 2.1 R66139, small inducible cytokine subfamily D (Cys-X3-Cys), member 1 (fractalkine, neurotactin)
IL7R 2.1 AA487121, interleukin 7 receptor
IGHG3 2.2 AA663981, immunoglobulin heavy constant gamma 3 (G3m marker)
Clone_N168K 2.6 g1847166, homo sapiens isolate donor N clone N168K immunoglobulin kappa light chain variable region mRNA
IFI30 2.7 AA630800, interferon, gamma-inducible protein 30
CD74 2.9 g712300, CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen associated)
HLA-DRB3 3.4 g1350342, major histocompatibility complex, class II, DR beta 3
HS3ST1 3.5 T55714, heparan sulfate (glucosamine) 3-O-sulfotransferase 1
Ig-partial_cds 3.9 g1791068, human immunoglobulin heavy chain variable region (V4-31) gene, partial cds
Ig_Partial_cds 4.7 g6927383, human rearranged immunoglobulin heavy chain mRNA, partial cds
MALT1 5.4 AA826328, mucosa-associated lymphoid tissue lymphoma translocation gene 1
LCN2 6.2 AA401137, lipocalin 2 (oncogene 24p3)
IL2 9.2 g2466805, Interleukin 2
SDF1 2.0 AA447115, stromal cell-derived factor 1
IL6ST 3.2 AA406546, interleukin 6 signal transducer (gp130, oncostatin M receptor)
Cell cycle/proliferation/differentiation:
FGFR1 2.0 AA281189, fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
RBBP7 2.0 AA995351, retinoblastoma-binding protein 7
TNFSF13 2.1 AA041396, tumor necrosis factor (ligand) superfamily, member 13
IGF1 4.5 N67876, insulin-like growth factor 1 (somatomedin C)
BST2 5.6 AA485371, bone marrow stromal cell antigen 2
EGR1 2.0 AA486628, early growth response 1
SMAP 2.1 AA481621, thyroid hormone receptor co-activating protein
SIX2 2.1 g2816419, Sine oculis homeobox (Drosophila) homolog 2
SUPT6H 2.1 R85545, suppressor of Ty (S.cerevisiae) 6 homolog
FHL1 2.1 AA456394, four and a half LIM domains 1
AIP-1 2.1 W19461, Abl-interactor 12 (SH3-containing protein)
VEGFC 2.3 H07991, vascular endothelial growth factor C
EDG2 2.6 AA193405, endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2
PDGFRA 4.9 H23235, platelet-derived growth factor receptor, alpha polypeptide
CUL3 5.2 R27581, cullin 3
WNT5A 6.4 W49672, wingless-type MMTV integration site family, member 5A
IGF2 9.1 H59614, insulin-like growth factor 2 (somatomedin A)
Cell death:
HIG2 2.3 AI343669, hypoxia-inducible protein 2
NME3 2.7 AA398218, non-metastatic cells 3, protein expressed in
CARD12 2.1 AA443290, caspase recruitment domain protein 12
ANXA5 2.8 AA451895, annexin A5
DNA repair:
PMS1 2.1 AA504838, postmeiotic segregation increased (S. cerevisiae) 1
Transcription related:
ATF5 2.1 AA496253, activating transcription factor 5
CEBPB 2.1 H26183, CCAAT/enhancer-binding protein (C/EBP), beta
BTF3 2.0 AA609731, basic transcription factor 3
MADH4 2.0 AA456439, MAD (mothers against decapentaplegic, Drosophila) homolog 4 (Smad4)
PLAGL1 2.0 AA463297, pleiomorphic adenoma gene-like 1
SMARCA5 2.0 AA416971, SWI/SNF related, matrix associated, actin-dependent regulator of chromatin, subfamily a, member 5
ZHX1 2.1 N50828, zinc-fingers and homeoboxes 1
JUN 2.3 W96155, v-jun avian sarcoma virus 17 oncogene homolog
SON 2.4 AA431848, DNA-binding protein
PBX3 2.6 W48726, pre-B-cell leukemia transcription factor 3
MAF 2.6 AA043501, v-maf musculoaponeurotic fibrosarcoma (avian) oncogene homolog
MYC 2.6 W87741, v-myc avian myelocytomatosis viral oncogene homolog
GTF3A 2.7 AA456147, general transcription factor IIIA
RUVBL1 2.8 AI023590, RuvB (E. coli homolog)-like 1
ZNF6 2.9 AA928817, zinc-finger protein 6 (CMPX1)
WT1 3.3 AA130187, Wilms tumor 1
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KLF4 3.6 H45711, Kruppel-like factor 4 (gut)
STAT3 3.8 AA399410, signal transducer and activator of transcription 3 (acute-phase response factor)
EIF5 4.6 AA669443, eukaryotic translation initiation factor 5
Cell signaling:
PRKCD 2.0 H11054, protein kinase C, delta
LYN 2.1 R83837, v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog
KSR1 2.1 H88143, kinase suppressor of ras
VAV1 2.1 T65770, Vav 1 oncogene
PLXNB1 2.2 AA496565, Plexin B1
PPFIA4 3.0 AI653137, protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4
RAN 2.0 AA456636, member RAS oncogene family
FYN 2.1 N22980, FYN oncogene related to SRC, FGR, YES
STATI2 2.1 R23241, STAT-induced STAT inhibitor-2
GJA1 2.1 AA487623, gap junction protein, alpha 1, 43kD (connexin 43)
PIM2 2.2 AA863383, Pim-2 oncogene
DVL2 2.4 R39405, dishevelled 2 (homologous to Drosophila dsh)
SGK 2.4 AA486082, serum/glucocorticoid regulated kinase
TNFSF11 2.5 AA504211, tumor necrosis factor (ligand) superfamily, member 11
RAB31 2.6 AA449333, RAB31, member RAS oncogene family
PIM1 3.7 N63635, Pim-1 oncogene
Adhesion, and extracellular matrix:
SELL 2.1 H00756, selectin L (lymphocyte adhesion molecule 1)
CHL1 2.2 H15267, cell adhesion molecule with homology to L1CAM (close homologue of L1)
MMP9 3.4 AA425227, matrix metalloproteinase 9 (gelatinase B, 92 kD gelatinase, 92 kD type IV collagenase)
COL15A1 2.1 AA464342, collagen, type XV, alpha 1
MMP19 2.1 AI361112, matrix metalloproteinase 19
CTNND1 2.1 AA024656, catenin (cadherin-associated protein), delta 1
CALD1 2.3 AA447737, caldesmon 1
COL5A2 3.2 AA461456, collagen, type V, alpha 2
COL1A2 3.2 AA490172, collagen, type I, alpha 2
ITM2B 3.4 AA453275, integral membrane protein 2B
COL5A1 3.4 R75635, collagen, type V, alpha 1
CDH11 3.5 H96738, cadherin 11, type 2, OB-cadherin (osteoblast)
CORO2B 3.6 N92783, coronin, actin-binding protein, 2B
COL6A3 3.6 R62603, collagen, type VI, alpha 3
CSPG2 3.6 AA101875, chondroitin sulfate proteoglycan 2 (versican)
SPARC 3.7 g839914, secreted protein, acidic, cysteine-rich (osteonectin)
CNTNAP1 18.1 AA028905, contactin-associated protein 1
Basic cellular function/miscellaneous:
CHD3 2.0 AA454980, chromodomain helicase-DNA binding protein 3
KIAA0677 2.0 AA620458, KIAA0677 gene product
EST 2.0 N23708, ESTs
EST 2.0 AA678087, ESTs
EVPL 2.0 AA029418, Envoplakin
FLJ23231 2.0 T97601, hypothetical protein FLJ23231
EST 2.0 AA682558, ESTs
EST 2.0 g1030258, ESTs
HD 2.1 T64094, Huntingtin (Huntington disease)
AGPAT2 2.1 AA938623, 1-acylglycerol-3-phosphate O-acyltransferase 2 (lysophosphatidic acid acyltransferase, beta)
KIAA0485 2.1 AI685539, KIAA0485 protein
FLJ21935 2.1 AA143726, hypothetical protein FLJ21935
AK1 2.1 AA775325, adenylate kinase 1
TBCD 2.1 AI668870, tubulin-specific chaperone d
KIAA1856 2.1 H40023, KIAA1856 protein
SULT1A3 2.1 AA398458, sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3
Clone_mcg53-54 2.1 g6925032, homo sapiens clone mcg53-54 immunoglobulin lambda light chain variable region 4a mRNA, partial
cds
UBD 2.3 N49629, diubiquitin
EST 2.4 AA699824, ESTs
EST 2.4 AA678361, ESTs
clone_ASPBLL54 2.4 g6923541, homo sapiens clone ASPBLL54 immunoglobulin lambda light chain VJ region mRNA, partial cds
FLJ20940 3.4 N34316, hypothetical protein FLJ20940
cDNA_2010107G23 3.4 AA452165, homo sapiens, Similar to RIKEN cDNA 2010107G23 gene, clone MGC:9596 IMAGE:3896656, mRNA,
complete cds
EST 3.5 H50747, ESTs
Clone_MGC_17279 4.6 N90491, clone MGC:17279 IMAGE:4212772, mRNA, complete cds
FEZ2 2.0 AA043280, fasciculation and elongation protein zeta 2 (zygin II)
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expression has been seen as a result of b-catenin nuclear
accumulation, in EC with CTNNB1 mutations. Transcription factor
RUNX1/AML1 has been found to be upregulated in EC during
invasion; and a cooperative role of ERM/ETV5 and RUNX1/AML1
during early steps of myometrial invasion has been proposed.72
EECs with myometrial invasion show higher number of CD163-
tumor macrophages and greater microvessel density than EECs
without myometrial invasion.73 In carcinomas confined to the
corpus uteri (stage I), expression of hypoxia-inducible factor 1a
subunit (HIF-1A) is associated with deep myoinvasion (stage IC).73
Also, high-grade EECs have more macrophage infiltrates and
microvessels than low-grade tumors. These findings suggest that
enhanced tumor angiogenesis, triggered by stromal macrophages
regulates the progression of EEC.
A proteomic approach has been recently taken to characterize
specific components of the invasive front or reactive stroma by
comparing the invasive area of a tumor with pure tumor and
normal tissue from the same patients.74 Some of these proteins
have been already described as specific of the invasive tumor
front, like Fascin1 in colorectal cancer, with a transient upregula-
tion that promotes the acquisition of migratory and invasive
phenotypes that lead to metastasis. Of interest resulted the
identification of different enzymes involved in oxidative stress, as
SOD1 or BLVRB. Reactive oxygen species (ROS) have been recently
proposed to be involved in tumor metastasis. ROS is generated
and ROS targets downstream molecules to trigger tumor
metastasis, especially in the initial stage that includes EMT and
cell migration.
APOPTOSIS RESISTANCE IN EC
Deregulation of apoptosis plays an important role in development
and progression of cancer. The lack of response to such stimuli
can originate a survival advantage, and the expansion of a
population of neoplastic cells. Moreover, cells resistant to
apoptosis are likely to escape the immune surveillance, but they
may be also resistant to therapy.
Several of the molecular abnormalities that have been detected
in EC may be associated with apoptosis deregulation. EEC show a
high frequency of mutations in PTEN, which lead to constitutively
active Akt, which in turn suppresses apoptosis triggered by
various stimuli. Moreover, the recent evidence that nuclear factor
(NF)-kB activation is frequent in EC75 may explain the presence of
apoptosis resistance by activation of target genes such as FLIP and
Bcl-XL. P53 alterations, which are characteristic of NEEC, may also
occur in EEC and they may have an impact in apoptosis at several
different levels. Also, members of the Bcl-2 family of genes are
abnormal in EC. In EC, divergent observations have been reported
with respect to Bcl-2 and Bcl-xL. Some authors have found
upregulated Bcl-xL and Bcl-2 in EC compared with normal tissue
and have also been reported to be involved in development of
metastases. However, others described high Bcl-2 levels in initial
hyperplasia but decreased expression of Bcl-2 in EC thereby
indicating a restrictive role for Bcl-2 in initial steps of EC
development. Many pathways can control Bcl-2 expression and
typical EC molecular alterations such as those involved in
exacerbated PI3K/AKT signaling could trigger Bcl-2 family
members overexpression.






EST 2.0 W52340, EST, weakly similar to A60764 Ig gamma-3 chain C region, form LAT
HRB2 2.0 W52273, HIV-1 rev binding protein 2
CYR61 2.0 AA777187, cysteine-rich, angiogenic inducer, 61
EST 2.0 g1102475, ESTs
FLJ22128 2.1 N34358, homo sapiens cDNA: FLJ22128 fis, clone HEP19543
HSPC207 2.1 H99997, hypothetical protein
KIAA1938 2.1 AA777448, KIAA1938 protein
KIAA1224 2.1 AA443116, KIAA1224 protein
EST 2.1 R33303, ESTs, weakly similar to I38022 hypothetical protein
ARIH1 2.1 AA188416, Ariadne (Drosophila) homolog, ubiquitin-conjugating enzyme E2-binding protein, 1
FLJ23249 2.1 AA625756, homo sapiens cDNA: FLJ23249 fis, clone COL04196
GNG11 2.1 AA999901, guanine nucleotide binding protein 11
CYP1B1 2.1 AA448157, cytochrome P450, subfamily I (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile)
KIAA0468 2.1 AA167273, KIAA0468 gene product
FLJ11658 2.1 R99080, homo sapiens cDNA FLJ11658 fis, clone HEMBA1004577
FLJ14368 2.1 AA131421, Homo sapiens cDNA FLJ14368 fis, clone HEMBA1001122
FLJ12815 2.2 AA046679, homo sapiens cDNA FLJ12815 fis, clone NT2RP2002546
HIBADH 2.3 N77326, 3-hydroxyisobutyrate dehydrogenase
CAV1 2.4 AA055835, caveolin 1, caveolae protein, 22kD
LHFPL2 2.4 AA863469, lipoma HMGIC fusion partner-like 2
EIF3S10 2.4 AA916914, eukaryotic translation initiation factor 3, subunit 10 (theta, 150/170kD)
PRO2032 2.5 AA287122, hypothetical protein PRO2032
THBD 2.5 H59861, thrombomodulin
FLJ20783 2.7 AA126862, hypothetical protein FLJ20783
Clone_MGC_5564) 2.7 H05769, homo sapiens, clone MGC:5564, mRNA, complete cds
CLIC4 2.9 AA634261, chloride intracellular channel 4
DKFZp761K1423 3.3 AA460826, hypothetical protein DKFZp761K1423
DKFZP434J214 3.7 AA707871, DKFZP434J214 protein
D2S448 4.3 AI356709, melanoma associated gene
KIAA1474 4.7 N70608, KIAA1474 protein
AD036 4.7 AA496988, AD036 protein
FLJ22059 4.9 N36421, hypothetical protein FLJ22059
ALDH1A2 14.1 AA447978, aldehyde dehydrogenase 1 family, member A2
DKFZp761M0223 16.3 AA404249, homo sapiens mRNA; cDNA DKFZp761M0223 (from clone DKFZp761M0223)
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Resistance to extrinsic apoptotic pathway represents an
excellent acquired phenotype for progression of different types
of tumor malignances. One of the most important regulators of
death receptor signaling is FLIP.76 A direct evidence of the role of
FLIP in TRAIL apoptosis resistance on EC cells is provided by
treatment with specific small interfering RNA targeting FLIP.
Transfection of EC cell lines with FLIP small interfering RNA
produces a marked decrease in cell viability after TRAIL exposition.
This is accompanied by activation of both caspase-8 and caspase-3
suggesting activation of the extrinsic pathway. Moreover, in EEC
FLIP can be transcriptionally regulated by casein kinase-2 (CK2), a
Ser/Thr kinase implicated in development and progression of many
neoplasias. This data further points to CK2 as an important
modulator of TRAIL sensitivity.67,68 In fact, CK2 b regulatory subunit
has been found overexpressed in EC compared with normal tissue
and to regulate cell proliferation and anchorage-independent cell
growth. Recent studies have shown that FLIP may be regulated by
a cellular complex composed by CK2--BRAF--KSR1.77-80 This is
interesting because that will connect apoptosis resistance with the
RAS--RAF--MEK--ERK signaling pathway.
The kinase suppressor of RAS 1 (KSR1) is considered a scaffold
protein that interacts and regulates the intensity and duration of
mitogen-activated protein kinase pathway. KSR1 can interact with
different kinases of the RAS--RAF--MEK--ERK signaling pathway to
enhance its activation. KSR1 is critical for Ras-induced transforma-
tion by active forms of Ras both in vitro and in vivo. KSR1
regulation of RAS--RAF--MEK--ERK has also been involved in
modulation of apoptotic response to death receptors. It has been
recently demonstrated that the expression of KSR1 is increased in
EC suggesting a possible role in endometrial carcinogenesis.
Inhibition of KSR1 expression by lentiviral delivered short hairpin
RNA in ECCs resulted in a marked reduction of both proliferation
and anchorage-independent cell growth properties of ECCs.
Interestingly, inhibition of KSR1 expression sensitized resistant
ECC lines to both TRAIL- and Fas-induced apoptosis by a
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Figure 1. Validation data of selected genes in the samples used in the analysis of cDNA arrays (series 1) and in another independent series
(series 2). Mean fold expression of all studied genes in EEC and semiquantitative reverse transcriptase --PCR. Significant differences between
EEC and NE for each of the analyzed genes are indicated at the top of the graph.
Figure 2. Immunohistochemical analysis of Smad4 (a --c), CD74 (d -- f ) in a tissue microarray containing 190 ECs. (a) Smad 4 is expressed in the
nuclei and cytoplasms of both epithelial and stromal cells in this normal proliferative endometrium. (b) A well-differentiated EEC showing
intense smad4 expression. (c) Absence of smad4 expression in a NEEC. Note the transition of smad4 expression in a gland containing both
normal and neoplastic cells (asterisk). (d) CD74 expression is seen is inflammatory cells in the stroma of a normal secretory endometrium.
Focal staining of some epithelial cells is also observed. (e) Extensive CD74 cytoplasmic expression in a well-differentiated EEC. (f ) Absence of
CD74 expression in a NEEC. Note the positivity of inflammatory cells scattered in the stroma.
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Apoptosis may be also subjected to targeted therapy. Protea-
some inhibitors are currently used as chemotherapeutic drugs
because of their ability to trigger cell growth arrest or apoptosis
on several tumors. In many different types of tumor cells,
Bortezomib and other proteasome inhibitors cause cell death by
blocking NF-kB activity. However, in EC, proteasome inhibitors
induce cell death, but, instead of blocking NF-kB, they increase its
transcriptional activity. Proteasome-inhibitor induced cell death
was accompanied by activation of caspases and apoptotic nuclear
morphology.81 Sorafenib was originally described as an inhibitor
of b- and c-RAF kinase, but has also activity against several
receptor tyrosine kinases, including vascular endothelial growth
factor receptor 2, platelet-derived growth factor receptor, FLT3,
Ret and c-Kit. There is recent evidence showing that Sorafenib
sensitize EC cells to TRAIL-induced apoptosis, by downregulating
FLIP, and Mcl-1.77
RESISTANCE TO HYPOXIA AND TO IONIZING RADIATION
TREATMENT
EC are treated by means of surgery with additional radiation.
Although a high percentage of patients with EC present a
favorable outcome, treatment fails in those with either advanced
stage or high histological grade EC. Post radiotherapy recurrences
are usually of poor prognosis, as they are usually associated with
increased risk of metastases. They are treated by chemotherapy.
Understanding the molecular and genetic mechanisms underlying
either radio and or chemotherapy treatment resistance is of crucial
importance for the establishment of new therapeutic targets, in
order to improve the outcome of EEC.
Among the mechanisms in radioresistance, tumor hypoxia has
been demonstrated to render tumors more resistant to ionizing
radiation treatment. By reacting with the radiation-created broken
ends of DNA, the oxygen fixes the damage and thus enhances
radiation induced cell death. This phenomenon is known as the
oxygen enhancement effect, which could render oxygenated cells
three times more radiosensitive than hypoxic cells. Under hypoxic
conditions, the oxygen enhancement effect is lost, and cells
become more radioresistant (Figure 4). Although the absence of
oxygen is the major factor inducing radioresistance under hypoxic
conditions, there are increasing evidences showing that signaling
pathways activated under hypoxia may modulate cancer cells
radioresistance.
Some investigators have addressed the molecular mechanisms
involved in resistance to radiotherapy in EC. PR expression and
polymorphisms in the gene coding for PR seem to play an
important role.82 Defective mismatch repair has also been looked
at in this setting. In one study,83 MLH1 promoter methylation and
decreased MLH1/MSH2 expression were not predictive of
recurrence in stage I EC, but ‘de novo’ MLH1 promoter methylation
was occasionally detected during tumor progression in patients
receiving radiation therapy. In another study,84 alterations in the
P53-suppressor gene were assessed in a series of patients with ECs
with and without recurrences. Finally, three components of the
Wnt pathway (APC, b-catenin and E-cadherin) were evaluated in a
small series of patients with stage I EC in correlation with
development of recurrence.85 Important information has been
obtained regarding the mechanisms of resistance to radiation, by
comparing by immunohistochemistry tissue microarrays from
post-radiation recurrences of EC with a group of primary EC.86
Results have revealed that post-radiation recurrences exhibited
increased expression b-catenin. In recent work, it has been
showed that hypoxia-induced b-catenin nuclear translocation
in EC Ishikawa and HEC-1A cell lines. Moreover, hypoxia induced
Table 2. Relationship between SMAD4, and CD74 expression and
clinicopathological features in endometrial carcinoma
SMAD 4 downregulation CD74 overexpression
n/nt (%)
Type:
EEC 56/99 (56.6) 103/119 (86.6)
NEEC 19/32 (59.4) 20/34 (58.8)
P¼ 0.780 Pp0.001
EEC
FIGO grade: 19/36 (52.8) 41/43 (95.3)
G1 (n¼ 36) 19/36 (52.8) 41/45 (91.1)
G2 (n¼ 36) 18/29 (42.9) 20/32 (62.5)
G3 (n¼ 29) P¼ 0.697 Pp0.001
Stage:
I 32/65 (49.2) 71/79 (51.4)
II 57/11 (45.5) 11/14 (78.6)
III - IV 3/ 7 (42.9) 5/8 (62.5)
P¼ 0.932 P¼ 0.069
NEEC
stage:
I 4/12 (33.3) 7/13 (53.8)
II 5/ 7 (71.4) 4/7 (57.1)
III - IV 9/10 (90.0) 7/10 (70.0)
P¼ 0.020 P¼ 0.724
Abbreviations: EEC, endometrioid endometrial carcinoma; n, positive cases







-Microsatellite Instability (M.I) (Ref: 5, 6, 7, 8, 9, 10, 11)
-PTEN mutation (Ref: 12, 13, 14, 15, 16, 17)
-K-RAS mutation (Ref: 28)
-PIK3CA mutation (Ref: 18, 19, 20, 21, 22, 23, 24, 25)
--catenin/ CTNNB1 mutation (Ref: 35, 36, 37, 38, 39)
-FGFR mutation (Ref: 32, 33, 34)
-p53 alteration (Ref: 40, 41, 42, 43, 44, 45)
-p16 inactivation (Ref: 42)
-E-cadherin inactivation (Ref: 42)
-c-erb B2 amplification (Ref: 42)
-cyclins D1 and E amplifications (Ref: 42)
Figure 3. There are many different types of EC; type I, endometrioid carcinoma, type II, non-endometrioid carcinoma, but also tumors showing
mixed and overlapping features.
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an increase in TCF-4 reporter (Wnt reporter) activity in both EC cell
lines previously cited.
HIF-1a is another candidate that could be involved in conferring
radioresistance to EC cells. HIF-1 is the most important mediator of
hypoxia, as it controls the expression of 4100 genes. It has been
recently shown that HIF-1a expression is increased in post-
radiation recurrences compared with primary EC, and that HIF-1a
controlled classical NF-kB activation pathway and survival under
hypoxia through RelA (p65) nuclear accumulation.87 Moreover, in
addition to the reported classical NF-kB activation pathway under
hypoxia, we have found that the alternative NF-kB pathway is also
activated under hypoxic conditions through HIF-1a-independent
pathway. Although IKKa and IKKb kinases control RelA(p65) and
p100 accumulation, p52 processing under hypoxia is exclusively
IKKa dependent. Both classical and alternative NF-kB pathways
enhanced EC cell survival under low oxygen tension. These results
may have a clinical application, as targeting the signaling
pathways on which hypoxic cell survival depends, may enable
oncologists to overcome tumor progression and resistance to
therapy.
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2 Matias-Guiu X, Catasús L, Bussaglia E, Lagarda H, Garcia A, Pons C et al. Molecular
pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32:
569 - 577.
3 Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: pathology
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mutations in endometrioid adenocarcinomas of the endometrium: evidence for a
tumor progression role in endometrioid carcinomas with microsatellite instability.
Lab Invest 1998; 78: 1439 - 1444.
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Figure 4. Hypoxia induces resistance to radiotherapeutic treatment:
Ishikawa (EC cell line) cells were seeded onto six-well plates. Cells
were either exposed to hypoxic conditions (1% O2) or maintained
under normoxia (21% O2) for 6 h, and then irradiated at the
indicated doses. Cells were then cultured for additional 14 days to
allow colony formation. After staining with MTT, the colony numbers
were counted. The graphic shows how the presence of oxygen
enhances sensitivity to ionizing radiation therapy.
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